(Q37013074)

17 August 2017

1 reference

title

Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure (English)

1 reference

17 August 2017

1 reference

dasatinib monohydrate

1 reference

1 reference

1 reference

Andreas Hochhaus

1

0 references

language of work or name

English

0 references

publication date

1 December 2007

1 reference

Expert Opinion on Pharmacotherapy

17 August 2017

published in

1 reference

17 August 2017

volume

8

1 reference

17 August 2017

issue

18

1 reference

17 August 2017

page(s)

3257-3264

1 reference

Clinical and epidemiologic burden of chronic myelogenous leukemia

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3257

Important therapeutic targets in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3257

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3257

Resistance to targeted therapy in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3257

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3257

Mechanisms of resistance to imatinib in CML patients: a paradigm for the advantages and pitfalls of molecularly targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3257

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3257

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3257

Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3257

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3257

New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3257

Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3257

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3257

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3257

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3257

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3257

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3257

Sequence-specific modification of a beta-thalassemia locus by small DNA fragments in human erythroid progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3257

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3257

The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3257

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3257

An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3257

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3257

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3257

10.1517/14656566.8.18.3257

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference